Sri Lanka healthcare market: size, growth and outlook 2026–2032

Universal public care with a growing private layer dependent on Indian pharma imports. Published estimates normalised to 2025 range from — to —; the Consulting Wallah central estimate is USD 3.2 bn, growing at about 6% a year to USD 4.8 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by ageing population (65+ share expected to double by 2030) and rising NCD burden; rising per-capita income driving demand for paid private healthcare; record private-hospital revenues in 2025 (Lanka Hospitals Rs 14.47 bn); post-crisis public investment revival: Rs 31 bn for Base Hospitals and Rs 45 bn revived project pipeline 2026-28.

Context that matters for buyers and suppliers: Public facilities deliver 95% of inpatient and 50% of outpatient care. 192 officially registered private hospitals (early 2025). India supplied ~49% of Sri Lanka's drug imports (USD 208.8 mn formulations, 2017); Pakistan 8%. Patented products are 15-18% of the pharma market; local production ~12% of units.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is —–—; differences are mostly scope.

Included: public and private hospital, clinic, diagnostic and long-term care services and the associated health expenditure. Excluded: pharmaceutical and device product sales, insurance premiums and health IT (covered in separate reports). Published totals differ mainly by whether products and insurance are folded in.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• Public facilities deliver 95% of inpatient and 50% of outpatient care (GTAI (Ministry of Health))
• 192 officially registered private hospitals (early 2025) (GTAI)
• India supplied ~49% of Sri Lanka's drug imports (USD 208.8 mn formulations, 2017); Pakistan 8% (Pharmexcil)
• Patented products are 15-18% of the pharma market; local production ~12% of units (Pharmexcil)
• SPC is the sole procurement agency for pharmaceuticals and surgical consumables for government institutions (Pharmexcil)
• Top five private hospitals hold 45% of private-sector bed capacity (Fitch via EconomyNext)
• Sri Lanka bed density ~3.9 per 1,000 vs India 1.6 and Pakistan 0.6 (CY20) (PACRA peer table)
• Health spend per capita ~USD 146 (2022), about double India's (GTAI / World Bank)

Where the GCC and India sit

• Private hospitals registered: 192 (Sri Lanka Journal of Medicine, early 2025) (2025) — GTAI
• Health expenditure per capita: ~USD 146 (World Bank, 2022), nearly 2x India's ~USD 79 (2022) — GTAI
• Bed density: ~3.9 beds per 1,000 (CY20), highest in South Asia peer set (2020) — PACRA (Pakistan healthcare study, peer table)
• MRI installed base: ~27 MRI scanners nationwide, mostly >10 years old (2025) — GTAI
• Health workforce emigration: ~20% of healthcare workers left during the 2021-24 crisis (expert estimate) (2025) — GTAI
• Ageing: ~9% of population aged 65+ (2015), expected to roughly double by 2030 (2015) — Fitch via EconomyNext

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: medtech market ~USD 294 mn (2025) forecast +26% by 2028; imaging, orthopaedics and consumables are largest import lines; private hospital consolidation and expansion into secondary cities (Colombo-centric today); indian generics supply (already ~49% of imports) and local manufacturing zone plans.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Operators and investors: capacity, payer rules and licensing timelines decide returns; design central procurement and insurer contracting into the operating model before opening.
• Suppliers: registration, a local partner and payer-formulary presence are the gates; central tenders reward structured quotations and reliable supply over the lowest price.
• Hospital leaders: payer pressure makes the 25–35% of cost in supplies the margin lever — see the free executive assessment.

1. GTAI, Sri Lanka - Medizintechnik (sector brief) — gtai.de
2. Pharmexcil, Sri Lanka country report (pharmaceuticals) — pharmexcil.com
3. Daily FT, Govt earmarks over Rs 21 b for nine new health projects as part of 2026 public investment push — ft.lk
4. Daily FT, Lanka Hospitals delivers record-breaking performance in 2025 — ft.lk
5. Daily FT, Lanka Hospitals presents 2025 Annual Report and five-year strategic roadmap — ft.lk
6. EconomyNext, Strong growth seen for Sri Lanka private hospitals: Fitch — economynext.com
7. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
8. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.